1. “1919MO Efficacy and Safety of Botensilimab (BOT) plus Balstilimab (BAL) in Patients (Pts) with Refractory Metastatic Sarcoma – Annals of Oncology” (n.d.). https://www.annalsofoncology.org/article/S0923-7534(23)01985-3/fulltext. Accessed 2 Dec 2023
2. “A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas – Full Text View – ClinicalTrials.Gov” (n.d.). https://classic.clinicaltrials.gov/ct2/show/NCT02812875?term=CA-170&draw=2&rank=1. Accessed 29 Nov 2023
3. “A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab – Full Text View – ClinicalTrials.Gov.” (n.d.). https://classic.clinicaltrials.gov/ct2/show/NCT05082610?term=HMBD-002&draw=2&rank=1. Accessed 29 Nov 2023
4. “A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors – Full Text View – ClinicalTrials.Gov.” (n.d.). https://classic.clinicaltrials.gov/ct2/show/NCT05864144?term=SNS-101+in+combination+with+cemiplimab&draw=2&rank=1. Accessed 29 Nov 2023
5. Abramiuk M, Grywalska E, Korona-Głowniak I, Niedźwiedzka-Rystwej P, Polak G, Kotarski J, Roliński J (2020) CD200 and CD200R expression on peripheral blood lymphocytes and serum CD200 concentration as a new marker of endometriosis. J Clin Med 9(9):3035. https://doi.org/10.3390/JCM9093035